p21: a monitor of p53 dysfunction in ovarian neoplasia
dc.contributor.author | Shigemasa, K. | en_US |
dc.contributor.author | Hu, C. | en_US |
dc.contributor.author | West, C. M. | en_US |
dc.contributor.author | Moon, S. H. | en_US |
dc.contributor.author | Parham, G. P. | en_US |
dc.contributor.author | Parmley, T. H. | en_US |
dc.contributor.author | Korourian, S. | en_US |
dc.contributor.author | Baker, V. V. | en_US |
dc.contributor.author | O'Brien, T. J. | en_US |
dc.date.accessioned | 2010-06-01T22:18:55Z | |
dc.date.available | 2010-06-01T22:18:55Z | |
dc.date.issued | 1997-07 | en_US |
dc.identifier.citation | SHIGEMASA, K . ; HU, C . ; WEST, C. M . ; MOON, S. H . ; PARHAM, G. P . ; PARMLEY, T. H . ; KOROURIAN, S . ; BAKER, V. V . ; O'BRIEN, T. J . (1997). "p21: a monitor of p53 dysfunction in ovarian neoplasia." International Journal of Gynecological Cancer 7(4): 296-303. <http://hdl.handle.net/2027.42/75326> | en_US |
dc.identifier.issn | 1048-891X | en_US |
dc.identifier.issn | 1525-1438 | en_US |
dc.identifier.uri | https://hdl.handle.net/2027.42/75326 | |
dc.format.extent | 190756 bytes | |
dc.format.extent | 3109 bytes | |
dc.format.mimetype | application/pdf | |
dc.format.mimetype | text/plain | |
dc.publisher | Blackwell Science Inc | en_US |
dc.rights | Blackwell Science Ltd, 1997 | en_US |
dc.subject.other | MRNA Expression | en_US |
dc.subject.other | Mutation Status | en_US |
dc.subject.other | Ovarian Cancer | en_US |
dc.subject.other | P21 | en_US |
dc.subject.other | P53 | en_US |
dc.title | p21: a monitor of p53 dysfunction in ovarian neoplasia | en_US |
dc.type | Article | en_US |
dc.subject.hlbsecondlevel | Obstetrics and Gynecology | en_US |
dc.subject.hlbtoplevel | Health Sciences | en_US |
dc.description.peerreviewed | Peer Reviewed | en_US |
dc.contributor.affiliationum | Division of Gynecology Oncology, University of Michigan Medical Center, Ann Arbor, Michigan, USA | en_US |
dc.contributor.affiliationother | Department of Obstetrics and Gynecology, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA, | en_US |
dc.contributor.affiliationother | Department of Biochemistry and Molecular Biology, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA, | en_US |
dc.contributor.affiliationother | Department of Pathology, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA, | en_US |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/75326/1/j.1525-1438.1997.00457.x.pdf | |
dc.identifier.doi | 10.1046/j.1525-1438.1997.00457.x | en_US |
dc.identifier.source | International Journal of Gynecological Cancer | en_US |
dc.identifier.citedreference | Boring CC, Squires TS, Tong T. Cancer Statistics 1992; 7: 19 – 38. | en_US |
dc.identifier.citedreference | Averette HE, Hoskins W, Nguyen HN, et al. National survey of ovarian carcinoma. Cancer 1993; 7: 1629 – 38. | en_US |
dc.identifier.citedreference | Hunter T. Cooperation between oncogenes. Cell 1991; 7: 249 – 70. | en_US |
dc.identifier.citedreference | Bast RC, Boyer CM, Jacobs I. et al. Cell growth retardation in epithelial ovarian cancer. Cancer 1993; 7: 1597 – 601. | en_US |
dc.identifier.citedreference | Kastan MB, Onyekwere O, Sidransky D, Vogelstein B, Craid RW. Participation of p53 protein in the cellular response to DNA damage. Cancer Res 1991; 7: 6304 – 11. | en_US |
dc.identifier.citedreference | Shah P, Bovey R, Tardy S, Sahli R, Sordat B, Costa J. Induction of apoptosis by wild-type p53 in a human colon tumor-derived cell line. Proc Natl Acad Sci USA 1992; 7: 4495 – 9. | en_US |
dc.identifier.citedreference | Lowe SW, Schmitt EM, Smith SW, Osborne BA, Jacks T. p53 is required for radiation-induced apoptosis in mouse thymocytes. Nature 1993; 7: 847 – 9. | en_US |
dc.identifier.citedreference | Xiong Y, Hannon GJ, Zhang H, Casso D, Kobayashi R, Beach D. p21 is a universal inhibitor of cyclin kinases. Nature 1993; 7: 701 – 4. | en_US |
dc.identifier.citedreference | El-Deiry WS, Tokino T, Velculescu VE, et al. WAF1, a potential mediator of p53 tumor suppression. Cell 1993; 7: 817 – 25. | en_US |
dc.identifier.citedreference | Harper JW, Adami GR, Wei N, Keyomarsi K, Elledge SJ. The p21 cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell 1993; 7: 805 – 16. | en_US |
dc.identifier.citedreference | Noda A, Ning Y, Venable SF, Pereira-Smith OM, Smith JR. Cloning of senescent cell-derived inhibitors of DNA synthesis using an expression screen. Exp Cell Res 1994; 7: 90 – 8. | en_US |
dc.identifier.citedreference | Shinohara M, El-Deiry WS, Wada M, et al. Absence of WAF1 mutation in a variety of human malignancies. Blood 1994; 7: 3781 – 4. | en_US |
dc.identifier.citedreference | Noonan KE, Beck C, Holzmayer TA, et al. Quantitative analysis of MDR1 (multi-drug resistance) gene expression in human tumors by polymerase chain reaction. Proc Natl Acad Sci USA 1990; 7: 7160 – 4. | en_US |
dc.identifier.citedreference | Lamb P & Crawford L. Characterization of the human p53 gene. Mol Cell biol 1986; 7: 1379 – 85. | en_US |
dc.identifier.citedreference | Hall JL, Dudley L, Dobner PR, Lewis SA, Cowan NJ. Identification of two human β-tubulin isotopes. Mol Cell Biol 1983; 7: 854 – 62. | en_US |
dc.identifier.citedreference | Weinberg RA. The retinoblastoma protein and cell cycle control. Cell 1995; 7: 323 – 30. | en_US |
dc.identifier.citedreference | Nigro JM, Baker SJ, Preisinger AC, et al. Mutations in the p53 gene occur in diverse human tumour types. Nature 1989; 7: 705 – 8. | en_US |
dc.identifier.citedreference | Kupryjanczyk J, Thor AD, Beauchamp R, et al. p53 gene mutation and protein accumulation in human ovarian cancer. Proc Natl Acad Sci USA 1993; 7: 4961 – 5. | en_US |
dc.identifier.citedreference | Milner BJ, Allan LA, Eccles DM, et al. p53 mutation is a common genetic event in ovarian carcinoma. Cancer Res 1993; 7: 2128 – 32. | en_US |
dc.identifier.citedreference | Kohler MF, Marks JR, Wiseman RW, et al.. Spectrum of mutation and frequency of allelic deletion of the p53 gene in ovarian cancer. J Natl Cancer Inst 1993; 7: 1513 – 19. | en_US |
dc.identifier.citedreference | Niwa K, Itoh M, Murase T, et al. Alteration of p53 gene in ovarian carcinoma: Clinicopathological correlation and prognostic significance. Br J Cancer 1994; 7: 1191 – 7. | en_US |
dc.identifier.citedreference | McManus DT, Yap EPH, Maxwell P, Russel SEH, Toner PG, McGee J’OD. p53 expression, mutation, and allelic deletion in ovarian cancer. J Pathol 1994; 7: 159 – 68. | en_US |
dc.identifier.citedreference | Teneriello MG, Ebina M, Linnoila RI, et al. p53 and K-ras gene mutations in epithelial ovarian neoplasms. Cancer Res 1993; 7: 3103 – 8. | en_US |
dc.identifier.citedreference | Levine AJ, Perry ME, Chang A, et al. The role of the p53 tumor-suppressor gene in tumorigenesis. Br J Cancer 1994; 7: 409 – 16. | en_US |
dc.identifier.citedreference | Rogel A, Popliker M, Webb CG, Oren M, Webb CG, Oren M. p53 cellular tumor antigen: Analysis of mRNA levels in normal adult tissues, embryos and tumors. Mol Cell Biol 1985; 7: 2851 – 5. | en_US |
dc.identifier.citedreference | Finlay CA, Hinds PW, Tan TH, Eliyahu D, Oren M, Levine AJ. Activating mutations for transformation by p53 produce a gene product that forms a hsc70-p53 complex with an altered half-life. Mol Cell Biol 1988; 7: 531 – 9. | en_US |
dc.identifier.citedreference | Werness BA, Levine AJ, Howley PM. Association of human papillomavirus types 16 and 18 E6 proteins with p53. Science 1990; 7: 76 – 9. | en_US |
dc.identifier.citedreference | Chen J, Marechal V, Levine AJ. Mapping of the p53 and mdm-2 interaction domains. Mol Cell Biol 1993; 7: 107 – 14. | en_US |
dc.identifier.citedreference | Oliner JD, Pietenpol JA, Thiagalingam S, Gyures J, Kinzler KW, Vogelstein B. Oncoprotein MDM2 conceals the activation domain of tumor suppressor p53. Nature 1993; 7: 857 – 60. | en_US |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.